Penumbra Indigo 经皮抽吸取栓系统治疗主动脉腔内移植物髂支闭塞:意大利多中心注册研究结果
该回顾性观察性多中心研究在8个意大利血管中心纳入17例EVAR后髂支闭塞患者,评估Penumbra Indigo经皮抽吸取栓系统的安全性和有效性。Indigo PAT后82%患者达到TIPI 2-3级再通,联合辅助手术后达94%;12个月内临床成功100%且无髂支闭塞复发。
要点
- EVAR后髂支闭塞患者中,Indigo PAT单用技术成功率为82%,联合辅助手术后为94%。
- 12个月随访期间临床成功率为100%,无髂支闭塞复发。
- 术中远端栓塞发生率为6%,30天死亡率为6%(肺炎所致)。
核心结论
- 该研究首次报告Penumbra Indigo PAT治疗EVAR后髂支闭塞的有效性和安全性,术后1年内技术和临床成功率良好。
研究设计与样本
- 回顾性观察性多中心研究,在8个意大利血管中心开展,连续纳入EVAR后髂支闭塞患者。
- 2019年9月至2021年12月期间,共纳入17例患者(48处髂支闭塞),中位年龄75岁(IQR 71,83岁),男性14例(82%),急诊8例(47%)。
- 中位距初次EVAR时间24个月(IQR 0,42个月),中位血栓年龄(从髂支闭塞诊断至PAT)3天(IQR 1,12天)。
- 10例患者(59%)表现为肢体威胁性缺血;术前TIPI 0级13例(76%),TIPI 1级4例(24%)。
主要发现
- PAT后(t2),单用Indigo PAT的技术成功(TIPI 2-3级)14例(82%),p < .001。
- 15例患者(88%)需要辅助手术(14例重新内衬,1例外科补片血管成形术);联合技术成功(t3)16例(94%)。
- 术中并发症为1例(6%)远端栓塞,经治疗成功。
- 30天死亡1例(6%),死于肺炎。
- 1、6、12个月临床成功率均为100%,无髂支闭塞复发;中位随访23个月(IQR 11,41个月),18个月时生存率和免于再干预率分别为91 ± 8%和90 ± 9%。
关键数值与推荐
- 血管再通评估采用血栓抽吸在外周缺血中的分类(TIPI分类,评分0-3分),在术前(t1)、PAT后(t2)和辅助手术后(t3)进行。
- 成功再通定义为TIPI 2-3级(接近完全或完全)。
- 主要术中结局为Indigo PAT的技术成功及需要时PAT联合辅助手术的联合技术成功。
- 主要随访结局为1、6、12个月的安全性和有效性。
临床怎么用
- 作者认为Penumbra Indigo PAT治疗EVAR后髂支闭塞有效且安全,术后1年内技术和临床成功率良好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to evaluate the safety and effectiveness of the Penumbra Indigo percutaneous aspiration thrombectomy (PAT) system in the clinical presentation of iliac limb occlusion (ILO) after endovascular aortic repair (EVAR). METHODS: A retrospective, observational, multicentre study conducted in eight Italian vascular centres. Consecutive patients presenting with ILO after EVAR were eligible. To assess vessel revascularisation, Thrombo-aspiration In Peripheral Ischaemia (TIPI) classification (score 0-3) was used at presentation (t1), after PAT (t2), and after adjunctive procedures (t3). Successful revascularisation was considered TIPI 2-3 (near complete or complete). Primary intra-operative outcomes were technical success (TS) of Indigo PAT and combined TS of PAT associated with adjunctive procedures when needed. Primary follow up outcomes were safety and effectiveness at one, six, and 12 months. RESULTS: From September 2019 to December 2021, there were 48 ILO and 17 patients (35%) [median age 75 years, IQR 71, 83 years; male, 14 (82%); urgent, 8 (47%)] were treated and enrolled. The median time after primary EVAR was 24 months (IQR 0, 42 months). The median clot age from ILO diagnosis to PAT was three days (IQR 1, 12 days). Ten patients (59%) presented with limb threatening ischaemia. At t1, TIPI 0 and 1 was present in 13 (76%) and four (24%) cases, respectively. At t2, primary TS (TIPI 2-3) was achieved in 14 cases (82%) after Indigo PAT (p < .001). Fifteen patients (88%) required adjunctive procedures (14 re-linings, one surgical patch angioplasty). At t3, combined TS was achieved in 16 cases (94%). Intra-operative complication included one (6%) distal embolisation, treated successfully. The 30 day mortality was one case (6%) due to pneumonia. At one, six, and 12 months, clinical success was 100% without ILO recurrence. The median follow up was 23 months (IQR 11, 41 months): at 18 months, survival and freedom from re-intervention were 91 ± 8% and 90 ± 9%, respectively. CONCLUSION: This study reports for the first time the efficacy and safety of Penumbra Indigo PAT for ILO after EVAR, with promising technical and clinical success up to one year.
引用
- Spath P, Pasqui E, Angiletta D, et al. Penumbra Indigo Percutaneous Aspiration Thrombectomy System in the treatment of Aortic Endograft Iliac Limb Occlusion: Results from an Italian Multicentre Registry. Eur J Vasc Endovasc Surg. 2023. PMID: 37084878. doi:10.1016/j.ejvs.2023.04.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。